Genovis AB (GENO) - Financial and Strategic SWOT Analysis Review
Genovis AB (GENO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
Genovis AB (Genovis) develops, produces and markets enzyme products, which facilitate the development and quality control of biological drugs. The company’s products are used for antibody molecules analysis to identify and characterize proteins, antibody based biotherapeutics; monoclonal antibodies, antibody drug conjugates and biosimilars. Its SmartEnzymes product portfolio encompasses Fabricator (IdeS), Gingiskhan (KGP), Fabulous (SpeB), Glycinator (EndoS49), Fabricator Z (IdeZ), Gingisrex (Rgp), and IgGzero (EndoS). Genovis also offers antibody fragmentation services for different species and subclasses of Immunoglobulin G antibodies. The company offers its products to researchers at pharmaceutical and biotechnology companies, and academic institutions. It has presence in the US; Europe. Genovis is headquartered in Lund, Sweden.
Genovis AB Key Recent Developments
Aug 12,2021: Genovis: Half-year report for the first half of 2021
Apr 29,2021: Genovis : Interim report January – March 2021
Mar 29,2021: Genovis CFO has resigned
Dec 10,2020: Genovis and Glykos partner to enable new ADC platform
Nov 05,2020: Genovis : Report for the third quarter of 2020
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile contains critical company information including:
- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Genovis AB (Genovis) develops, produces and markets enzyme products, which facilitate the development and quality control of biological drugs. The company’s products are used for antibody molecules analysis to identify and characterize proteins, antibody based biotherapeutics; monoclonal antibodies, antibody drug conjugates and biosimilars. Its SmartEnzymes product portfolio encompasses Fabricator (IdeS), Gingiskhan (KGP), Fabulous (SpeB), Glycinator (EndoS49), Fabricator Z (IdeZ), Gingisrex (Rgp), and IgGzero (EndoS). Genovis also offers antibody fragmentation services for different species and subclasses of Immunoglobulin G antibodies. The company offers its products to researchers at pharmaceutical and biotechnology companies, and academic institutions. It has presence in the US; Europe. Genovis is headquartered in Lund, Sweden.
Genovis AB Key Recent Developments
Aug 12,2021: Genovis: Half-year report for the first half of 2021
Apr 29,2021: Genovis : Interim report January – March 2021
Mar 29,2021: Genovis CFO has resigned
Dec 10,2020: Genovis and Glykos partner to enable new ADC platform
Nov 05,2020: Genovis : Report for the third quarter of 2020
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
SECTION 1 - ABOUT THE COMPANY
Genovis AB - Key Facts
Genovis AB - Key Employees
Genovis AB - Key Employee Biographies
Genovis AB - Major Products and Services
Genovis AB - History
Genovis AB - Company Statement
Genovis AB - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
SECTION 2 – COMPANY ANALYSIS
Company Overview
Genovis AB - Business Description
Geographical Segment: Other Countries
Performance
Geographical Segment: Sweden
Performance
Genovis AB - Corporate Strategy
Genovis AB - SWOT Analysis
SWOT Analysis - Overview
Genovis AB - Strengths
Genovis AB - Weaknesses
Genovis AB - Opportunities
Genovis AB - Threats
Genovis AB - Key Competitors
SECTION 3 – COMPANY FINANCIAL RATIOS
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES
Genovis AB, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Genovis AB, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Genovis AB, Recent Deals Summary
SECTION 5 – COMPANY’S RECENT DEVELOPMENTS
Aug 12, 2021: Genovis: Half-year report for the first half of 2021
Apr 29, 2021: Genovis : Interim report January – March 2021
Mar 29, 2021: Genovis CFO has resigned
Dec 10, 2020: Genovis and Glykos partner to enable new ADC platform
Nov 05, 2020: Genovis : Report for the third quarter of 2020
Aug 13, 2020: GENOVIS: Half-Yearly Report January – June 2020
Apr 29, 2020: Genovis: Interim report January – March 2020
Mar 23, 2020: Nomination Committee proposes Torben Jorgensen for new chairman of Genovis
SECTION 6 – APPENDIX
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
Genovis AB - Key Facts
Genovis AB - Key Employees
Genovis AB - Key Employee Biographies
Genovis AB - Major Products and Services
Genovis AB - History
Genovis AB - Company Statement
Genovis AB - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
SECTION 2 – COMPANY ANALYSIS
Company Overview
Genovis AB - Business Description
Geographical Segment: Other Countries
Performance
Geographical Segment: Sweden
Performance
Genovis AB - Corporate Strategy
Genovis AB - SWOT Analysis
SWOT Analysis - Overview
Genovis AB - Strengths
Genovis AB - Weaknesses
Genovis AB - Opportunities
Genovis AB - Threats
Genovis AB - Key Competitors
SECTION 3 – COMPANY FINANCIAL RATIOS
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES
Genovis AB, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Genovis AB, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Genovis AB, Recent Deals Summary
SECTION 5 – COMPANY’S RECENT DEVELOPMENTS
Aug 12, 2021: Genovis: Half-year report for the first half of 2021
Apr 29, 2021: Genovis : Interim report January – March 2021
Mar 29, 2021: Genovis CFO has resigned
Dec 10, 2020: Genovis and Glykos partner to enable new ADC platform
Nov 05, 2020: Genovis : Report for the third quarter of 2020
Aug 13, 2020: GENOVIS: Half-Yearly Report January – June 2020
Apr 29, 2020: Genovis: Interim report January – March 2020
Mar 23, 2020: Nomination Committee proposes Torben Jorgensen for new chairman of Genovis
SECTION 6 – APPENDIX
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
LIST OF TABLES
Genovis AB, Key Facts
Genovis AB, Key Employees
Genovis AB, Key Employee Biographies
Genovis AB, Major Products and Services
Genovis AB, History
Genovis AB, Subsidiaries
Genovis AB, Key Competitors
Genovis AB, Ratios based on current share price
Genovis AB, Annual Ratios
Genovis AB, Annual Ratios (Cont...1)
Genovis AB, Annual Ratios (Cont...2)
Genovis AB, Interim Ratios
Genovis AB, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Genovis AB, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Genovis AB, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
Genovis AB, Key Facts
Genovis AB, Key Employees
Genovis AB, Key Employee Biographies
Genovis AB, Major Products and Services
Genovis AB, History
Genovis AB, Subsidiaries
Genovis AB, Key Competitors
Genovis AB, Ratios based on current share price
Genovis AB, Annual Ratios
Genovis AB, Annual Ratios (Cont...1)
Genovis AB, Annual Ratios (Cont...2)
Genovis AB, Interim Ratios
Genovis AB, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Genovis AB, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Genovis AB, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
LIST OF FIGURES
Genovis AB, Performance Chart (2016 - 2020)
Genovis AB, Ratio Charts
Genovis AB, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Genovis AB, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021
Genovis AB, Performance Chart (2016 - 2020)
Genovis AB, Ratio Charts
Genovis AB, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Genovis AB, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021